The potential autocrine/paracrine roles of ghrelin and its receptor in hormone-dependent cancer

Cytokine and Growth Factor Reviews

Volumn 14, Issue 2, 2003, Pages 113-122

  Jeffery, Penny L ^a   Herington, Adrian C ^a   Chopin, Lisa K ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Ghrelin; Growth hormone (GH); Growth hormone secretagogue receptor (GHS R); Growth hormone secretagogues (GHSs); Insulin like growth factors (IGFs)

Indexed keywords

GHRELIN; GROWTH HORMONE; GROWTH HORMONE SECRETAGOGUE RECEPTOR;

AUTOCRINE EFFECT; BREAST CANCER; CANCER; GENE CONTROL; HORMONE RELEASE; HUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TISSUE GROWTH;

EID: 0037380842     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(02)00089-8     Document Type: Review

References (107)

1. Howard A, Feighner S, Cully D, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996;12(1):137-45.
2. Bowers CY, Momany F, Reynolds GA, Chang D, Hong A, Chang K. Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology 1980;106:663-7.
3. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984;114:1537-45.
4. Pong SS, Chaung LY, Dean DC, Nargund RP, Patchett AA, Smith RG. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol Endocrinol 1996;10:57-61.
5. Deghenghi R. Stuctural requirements of growth hormone secretagogues. In: Bercu B, Walker RF, editors. Growth hormone secretagogues in clinical practice. New York: Springer; 1998. p. 28-9.
6. Arvat E, Di Vito L, Maccagno B, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides 1997;18:885-91.
7. Camanni F, Ghigo E, Arvat E. Growth hormone-releasing peptides and their analogs. Front Neuroendocrinol 1998;19:47-72.
8. McKee KK, Palyha OC, Feighner SD, et al. Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Mol Endocrinol 1997;11:415-23.
9. Kaji H, Tai S, Okimura Y, et al. Cloning and characterisation of the 5′-flanking region of the human growth hormone secretagogue receptor gene. J Biol Chem 1998;273(51):1-10.
10. Kamegai J, Tamura H, Ishii S, Sugihara H, Wakabayashi I. Thyroid hormones regulate pituitary growth hormone secretagogue receptor gene expression. J Neuroendocrinol 2001;13:275-8.
11. Tamura H, Kamegai J, Sugihara H, Kineman RD, Frohman LA, Wakabayashi I. Glucocorticoids regulate pituitary growth hormone secretagogue receptor gene expression. J Neuroendocrinol 2000;12:481-5.
12. Petersenn S, Rasch AC, Penshorn M, Beil FU, Schulte HM. Genomic structure and transcriptional regulation of the human growth hormone secretagogue receptor. Endocrinology 2001;142:2649-59.
13. Katayama M, Nogami H, Nishiyama J, Kawase T, Kawamura K. Developmentally and regionally regulated expression of growth hormone secretagogue receptor mRNA in rat brain and pituitary gland. Neuroendocrinology 2000;72:333-40.
14. Barlier A, Zamora AJ, Grino M, et al. Expression of functional growth hormone secretagogue receptors in human pituitary adenomas: polymerase chain reaction, triple in situ hybridisation and cell culture studies. J Neuroendocrinol 1999;11:491-502.
15. Smith RG, Feighner S, Prendergast K, et al. A new orphan receptor involved in pulsatile growth hormone release. Trends Endocrinol Metab 1999;10(4):128-35.
16. Cheng K, Chan WWS, Butler B, Barrato A, Smith RG. Evidence for a role of protein kinase-C in His-D-Trp-Ala-D-Phe-Lys-amide induced growth hormone release from rat pituitary cells. Endocrinology 1991;129:3337-42.
17. Bodner M, Castrillo JL, Theill LE, Deerinck T, Ellisman M, Karin M. The pituitary-specific transcription factor GHF-1 is a homeobox-containing protein. Cell 1988;55:505-18.
18. Garcia A, Alvarez CV, Smith RG, Dieguez C. Regulation of Pit-1 expression by ghrelin and GHRP-6 through the GH secretagogue receptor. Mol Endocrinol 2001;15(9):1484-95.
19. Van der Ploeg L, Howard A, Smith RG, Feighner SD. Molecular cloning and characterisation of human, swine and rat growth hormone secretagogue receptors. In: Bercu B, Walker RF, editors. Growth hormone secretagogues in clinical practice. New York: Springer; 1998. p. 57-76.
20. Kojima M, Hosodo H, Date Y, Nakazato M, Matsuo H, Kanagawa K. Ghrelin is a growth hormone releasing acylated peptide from stomach. Nature 1999;402(6762):656-60.
21. Banks WA, Tschop M, Robinson SM, Heiman ML. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 2002;302(2):822-7.
22. Bednarek MA, Feighner SD, Pong SS, et al. Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J Med Chem 2000;43:4370-6.
23. 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland. J Endocrin Invest 2001;24:7-9.
24. Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesised in a distinct endocrine cell type in the gastrointestinal tract of rats and humans. Endocrinology 2000;141:4255-61.
25. Seoane LM, Tovar S, Baldelli R, et al. Ghrelin elicits a marked stimulatory effect on GH secretion in freely-moving rats. Eur J Endocrinol 2000;143:7-9.
26. Arvat E, Di Vito L, Broglio M, et al. Preliminary evidence that ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrin Invest 2000;23:493-5.
27. Peino R, Baldelli R, Rodriguez-Garcia J, et al. Ghrelin-induced growth hormone secretion in humans. Eur J Endocrinol 2000;143:11-4.
28. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000;85:4908-11.
29. Sun Y, Ahmed S, Smith RG. Generation and characterization of ghrelin knockout mice. In: Proceedings of the 84th Annual Meeting of the Endocrine Society. San Francisco, USA, 2002.
30. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001;409:194-8.
31. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;50:1714-9.
32. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000;407:908-13.
33. Masuda Y, Tanaka T, Inomata N, Ohnuma N, Kojima M, Kangawa K. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 2000;276:905-8.
34. Wren AM, Small CJ, Ward HC, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000;141:4325-8.
35. Muccioli G, Tschop M, Papotti M, Deghenghi R, Heiman M, Ghigo E. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol 2002;440(2/3):235-54.
36. Hosoda H, Kojima M, Matsuo H, Kangawa K, et al. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 2000;279:909-13.
37. Ukkola O, Ravussin E, Jacobson P, et al. Mutations in the preproghrelin/ghrelin gene associated with obesity in humans. J Clin Endocrinol Metab 2001;86:3996-9.
38. Tanaka M, Hayashida Y, Nakao N, Nakai N, Nakashima K. Testis-specific and developmentally induced expression of a ghrelin gene-derived transcript that encodes a novel polypeptide in the mouse. Biochim Biophys Acta 2001;1522:62-5.
39. Jeffery PL, Herington AC, Chopin LK. Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. J Endocrinol 2002;172:7-11.
40. Sakata I, Nakamura K, Yamazaki M, Matsubara M, Hayashi Y, Kangawa K, et al. Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides 2002;23(3):531-6.
41. Bowers C. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab 2001;86:1464-9.
42. Gualillo O, Caminos JE, Blancos M, et al. Ghrelin, a novel placental-derived hormone. Endocrinology 2001;142:788-94.
43. Hattori N, Saito T, Yagyu T, Jiang BH, Kitagawa K, Inagaki C. GH, GH receptor, GH secretagogue receptor, and ghrelin expression in human T cells, B cells, and neutrophils. J Clin Endocrinol Metab 2001;86:4284-91.
44. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002;87(6):2988-91.
45. Korbonits M, Ciccarelli E, Ghigo E, Grossman A. The growth hormone secretagogue receptor. Growth Horm IGF Res 1999;9:93-9.
46. Mori K, Yoshimoto A, Takaya K, et al. Kidney produces a novel acylated peptide, ghrelin. FEBS Lett 2000;486:213-6.
47. 125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with atherosclerosis. Br J Pharmacol 2001;134:143-9.
48. Popovic V, Damjanovic S, Micic D, et al. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxford) 1998;49:441-5.
49. Jenkins PJ, Besser M. Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab 2001;86:2935-41.
50. Cheung NW, Boyages SC. Increased incidence of neoplasia in females with acromegaly. Clin Endocrinol (Oxford) 1997;47:323-7.
51. Bustin SA, Jenkins PJ. The growth hormone-insulin-like growth factor-I axis and colorectal cancer. Trends Mol Med 2001;7:447-54.
52. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83:2730-4.
53. Shim M, Cohen P. IGFs and human cancer: implications regarding the risk of growth hormone therapy. Horm Res 1999;51:42-51.
54. Colao A, Marzullo P, Spiezia S, et al. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. J Clin Endocrinol Metab 1999;84:1986-91.
55. Maison P, Balkau B, Simon D, Chanson P, Rosselin G, Eschwege E. Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. Br Med J 1998;316:1132-3.
56. Hankinson SE, Willet WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
57. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor I and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:911-5.
58. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
59. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000;18(4):847.
60. Li BD, Khosravi MJ, Berkel HJ, et al. Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 2001;91:736-9.
61. Pollak M, Costantino J, Polychronakos C, et al. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990;82:1693-7.
62. Holly JMP, Gunnell DJ, Davey Smith G. Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer? J Endocrinol 1999;162:321-30.
63. Pollak MN. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 1998;47(3):209-17.
64. Maiorano E, Loverro G, Viale G, Giannini T, Napoli A, Perlino E. Insulin-like growth factor-I expression in normal and diseased endometrium. Int J Cancer 1999;80:188-93.
65. Yu H, Berkel H. Insulin-like growth factors and cancer. J La State Med Soc 1999;151:218-23.
66. Hoeflich A, Reisinger R, Lahm H, et al. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 2001;61(24):8601-10.
67. Chopin LK, Herington AC. The growth hormone-insulin-like growth factor axis in prostate cancer. Clin Biochem Rev 1999;20:3-16.
68. Baxter RC, Butt AJ, Schedlich LJ, Martin JL. Antiproliferative and pro-apoptotic activities of insulin-like growth factor-binding protein-3. Growth Horm IGF Res 2000;10:S10-1.
69. Ilkbahar YN, Thordarson G, Camarillo IG, Talamantes F. Differential expression of the growth hormone receptor and growth hormone-binding protein in epithelia and stroma of the mouse mammary gland at various physiological stages. J Endocrinol 1999;161:77-87.
70. Swanson SM, Unterman TG. The growth hormone-deficient Spontaneous Dwarf rat is resistant to chemically induced mammary carcinogenesis. Carcinogenesis 2002;23(6):977-82.
71. Kaulsay KK, Mertani HC, Tornell J, Morel G, Lee K, Lobie PE. Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone. Exp Cell Res 1999;250:35-50.
72. Graichen R, Liu D, Sun Y, Lee KO, Lobie PE. Autocrine human growth hormone inhibits placental transforming growth factor-beta gene transcription to prevent apoptosis and allow cell cycle progression of human mammary carcinoma cells. J Biol Chem 2002;277:26662-72.
73. Gebre-Medhin M, Kindblom LG, Wennbo RF, Tomell J, Meis-Kindblom JM. Growth hormone receptor is expressed in human breast cancer. Am J Pathol 2001;158:1217-22.
74. Untergasser G, Rumpold H, Hermann M, Dirnhofer SG, Berger P. Proliferative disorders of the aging human prostate: involvement of protein hormones and their receptors. Exp Gerontol 1999;34:275-87.
75. Reiter E, Kecha O, Hennuy B, et al. Growth hormone directly affects the function of the different lobes of the rat prostate. Endocrinology 1995;136:3338-45.
76. Prieto JC, Carmena MJ. Growth hormone binding and stimulation of amino acid uptake in epithelial cells of rat ventral prostate. Cell Biochem Funct 1987;5:63-8.
77. Chopin LK, Veveris-Lowe TL, Philipps AF, Herington AC. Co-expression of GH and GHR isoforms in prostate cancer cell lines. Growth Horm IGF Res 2002;12(2):126.
78. Kolle S, Sinowatz F, Boie G, Temmim-Baker L, Lincoln D. Expression of growth hormone receptor in human prostatic carcinoma and hyperplasia. Int J Oncol 1999;14:911-6.
79. Thapar K, Kovacs K, Stefaneanu L, et al. Overexpression of the growth hormone releasing hormone gene in acromegaly associated pituitary tumours. An event associated with neoplastic progression and aggressive behaviour. Am J Pathol 1997;151(3):769-84.
80. Pinski J, Schally AV, Groot K, et al. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J Natl Cancer Inst 1995;87:1787-94.
81. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci USA 1997;94:5810-3.
82. Kiaris H, Schally AV. Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. Proc Natl Acad Sci USA 1999;96:226-31.
83. Szepeshazi K, Schally AV, Groot K, Armatis P, Hebert F, Halmos G. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours. Eur J Cancer 2000;36:128-36.
84. Szepeshazi K, Schally AV, Groot K, et al. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer 2000;82:1724-31.
85. Kahan Z, Arencibia JM, Csernus VJ, et al. Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab 1999;84:582-9.
86. Chatzistamou I, Schally AV, Varga JL, et al. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice. J Clin Endocrinol Metab 2001;86:2144-52.
87. Szepeshazi K, Schally AV, Armatis P, et al. Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. Endocrinology 2001;142:4371-8.
88. Chatzistamou I, Schally AV, Varga JL, et al. Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anticancer Drugs 2001;12:761-8.
89. Schally A, Varga J. Antagonistic analogs of growth hormone releasing hormone: new potential antitumour agents. Trends Endocrinol Metab 1999;10(10):383-91.
90. Chopin LK, Herington AC. A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines. Prostate 2001;49:116-21.
91. Asa SL, Kovacs K, Thorner MO, Leong DA, Rivier J, Vale W. Immunohistological localization of growth hormone-releasing hormone in human tumors. J Clin Endocrinol Metab 1985;60:423-7.
92. Khorram O, Garthwaite M, Grosen E, Golos T. Human uterine and ovarian expression of growth hormone-releasing hormone messenger RNA in benign and malignant gynecologic conditions. Fertil Steril 2001;75:174-9.
93. Korbonits M, Bustin SA, Kojima M, et al. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary tissue and other neuroendocrine tumours. J Clin Endocrinol Metab 2001;86:881-7.
94. Kim K, Arai K, Sanno N, Osamura RY, Teramoto A, Shibasaki T. Ghrelin and growth hormone (GH) secretagogue receptor (GHSR) mRNA expression in human pituitary adenomas. Clin Endocrinol (Oxford) 2001;54:759-68.
95. Skinner M, Nass R, Lopes B, Laws E, Thorner O. Growth hormone secretagogue receptor expression in human pituitary tumours. J Clin Endocrinol Metab 1998;83:4314-20.
96. Korbonits M, Jacobs RA, Aylwin SJB, et al. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumours. J Clin Endocrinol Metab 1998;83:3624-30.
97. Cassoni P, Papotti M, Catapano F, Deghenghi R, Ghigo E, Muccioli G. Specific binding sites for synthetic growth hormone secretagogues in non-tumoural and neoplastic human thyroid tissue. J Endocrinol 2000;165:139-46.
98. Kanamoto N, Akamizu T, Hosoda H, et al. Substantial production of ghrelin by a human medullary thyroid carcinoma cell line. J Clin Endocrinol Metab 2001;86:4984-90.
99. Cassoni P, Papotti M, Ghe C, et al. Identification, characterisation, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab 2001;86:1738-45.
100. Papotti M, Ghe C, Cassoni P, et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 2000;85:3803-7.
101. Papotti M, Cassoni P, Volante M, Deghenghi R, Muccioli G, Ghigo E. Ghrelin-producing endocrine tumors of the stomach and intestine. J Clin Endocrinol Metab 2001;86:5052-9.
102. Volante M, Allia E, Gugliotta P, et al. Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab 2002;87:1300-8.
103. Pettersson I, Muccioli G, Granata R, et al. Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. J Endocrinol 2002;175(1):201-9.
104. Murata M, Okimura Y, Iida K, et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 2001;277:5667-74.
105. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;8(3):813-22.
106. Sattler HP, Lensch R, Rohde V, et al. Novel amplification unit at chromosome 3q25-q27 in human prostate cancer. Prostate 2000;45:207-15.
107. Sugita M, Tanaka N, Davidson S, et al. Molecular definition of a small amplification domain within 3q26 in tumors of cervix, ovary, and lung. Cancer Genet Cytogenet 2000;117:9-18.